Nanomaterials in the treatment and diagnosis of rheumatoid arthritis: Advanced approaches DOI Creative Commons
Stefanny Angela,

Gianna Fadhilah,

Wesley Wei‐Wen Hsiao

et al.

SLAS TECHNOLOGY, Journal Year: 2024, Volume and Issue: 29(4), P. 100146 - 100146

Published: June 5, 2024

Rheumatoid arthritis (RA), a chronic inflammatory condition that affects persons between the ages of 20 and 40, causes synovium inflammation, cartilage loss, joint discomfort as some its symptoms. Diagnostic techniques for RA have traditionally been split into two main categories: imaging serological tests. However, significant issues are associated with both these methods. Imaging methods costly only helpful in people obvious symptoms, while assays time-consuming require specialist knowledge. The drawbacks traditional led to development novel diagnostic approaches. unique properties nanomaterials make them well-suited biosensors. Their compact dimensions frequently cited their outstanding performance, positive impact on signal-to-noise ratio accounts capacity detect biomarkers at low detection limits, excellent repeatability robust dynamic range. In this review, we discuss use theranostics. Scientists recently synthesized, characterized, modified commonly used enhance diagnosis therapy capabilities. We hope provide scientists promising potential hold future theranostics offer suggestions further improving biosensors, particularly detecting autoimmune disorders.

Language: Английский

Cartilage-Related Collagens in Osteoarthritis and Rheumatoid Arthritis: From Pathogenesis to Therapeutics DOI Open Access
Ziwei Ouyang,

Lei Dong,

Yao Feng

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(12), P. 9841 - 9841

Published: June 7, 2023

Collagens serve essential mechanical functions throughout the body, particularly in connective tissues. In articular cartilage, collagens provide most of biomechanical properties extracellular matrix for its function. Collagen plays a very important role maintaining cartilage and stability ECM. Noteworthily, many pathogenic factors course osteoarthritis rheumatoid arthritis, such as injury, inflammation, senescence, are involved irreversible degradation collagen, leading to progressive destruction cartilage. The collagen can generate new biochemical markers with ability monitor disease progression facilitate drug development. addition, also be used biomaterial excellent low immunogenicity, biodegradability, biocompatibility, hydrophilicity. This review not only provides systematic description analyzes structural characteristics mechanisms damage states but detailed characterization biomarkers production repair, providing ideas techniques clinical diagnosis treatment.

Language: Английский

Citations

43
Metal‐Organic Frameworks (MOFs): Classification, Synthesis, Modification, and Biomedical Applications DOI
Dayang Wang,

Huanchen Yao,

Jiashuo Ye

et al.

Small, Journal Year: 2024, Volume and Issue: 20(47)

Published: Aug. 16, 2024

Abstract Metal‐organic frameworks (MOFs) are a new variety of solid crystalline porous functional materials. As an extension inorganic materials, it has made important progress in preparation and application. MOFs widely used various fields such as gas adsorption storage, drug delivery, sensing, biological imaging due to their high specific surface area, porosity, adjustable pore size, abundant active sites, modification by introducing groups. In this paper, the types classified, synthesis methods mechanisms materials summarized. Finally, application prospects challenges metal‐organic framework biomedical field discussed, hoping promote multidisciplinary fields.

Language: Английский

Citations

17
Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options DOI Creative Commons
Slavica Pavlov‐Dolijanović, Milan Bogojević,

Tatjana Nožica-Radulović

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(10), P. 1878 - 1878

Published: Oct. 23, 2023

Elderly-onset rheumatoid arthritis (EORA) is a distinct clinical entity defined as the onset of (RA) in individuals aged over 60 years. EORA presents unique features, including more equitable distribution sexes, potential predilection for male involvement, higher incidence acute characterized by constitutional symptoms, propensity systemic manifestations, elevated sedimentation rates at disease onset, reduced occurrence factor positivity, increased titers anti-citrullinated protein antibodies, preference involvement large joints, activity, presence bone erosions, and heightened patient disability. RA recognized to consist three partially overlapping subsets. One subset mirrors classical presentation, while remaining subsets exhibit either polymyalgia rheumatica-like phenotype or present with remitting seronegative symmetrical synovitis accompanied pitting edema syndrome. In initial stages management, non-steroidal anti-inflammatory drugs (NSAIDs) are not typically first-line treatment choice, because seniors much prone develop side effects due NSAIDs, use NSAIDs reality contraindicated majority comorbidities. Disease-modifying antirheumatic (DMARDs), frequently methotrexate, introduced immediately after diagnosis made. cases where elderly patients demonstrate resistance conventional DMARD therapy, introduction biological targeted synthetic DMARDs becomes viable option. profile, necessitating tailored strategies. Our study emphasizes challenges NSAID seniors, highlighting imperative shift toward such methotrexate. Future research should explore personalized approaches based on comorbidities, safety considerations, aiming optimize outcomes minimize glucocorticoid reliance, thereby enhancing quality care patients.

Language: Английский

Citations

22
Nanotechnology-empowered combination therapy for rheumatoid arthritis: principles, strategies, and challenges DOI Creative Commons

Shujing Ren,

Yuhang Xu,

Xingpeng Dong

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: July 22, 2024

Abstract Rheumatoid arthritis (RA) is an autoimmune disease with multifactorial etiology and intricate pathogenesis. In RA, repeated monotherapy frequently associated inadequate efficacy, drug resistance, severe side effects. Therefore, a shift has occurred in clinical practice toward combination therapy. However, conventional therapy encounters several hindrances, including low selectivity to arthritic joints, short half-lives, varying pharmacokinetics among coupled drugs. Emerging nanotechnology offers incomparable opportunity for developing advanced against RA. First, it allows co-delivering multiple drugs augmented physicochemical properties, targeted delivery capabilities, controlled release profiles. Second, enables therapeutic nanomaterials development, thereby expanding regimens include multifunctional nanomedicines. Lastly, facilitates the construction of all-in-one nanoplatforms assembled modalities, such as phototherapy, sonodynamic therapy, imaging. Thus, promising solution current bottleneck both RA treatment diagnosis. This review summarizes rationale, advantages, recent advances nano-empowered It also discusses safety considerations, drug–drug interactions, potential translation. Additionally, provides design tips outlook on future developments The objective this achieve comprehensive understanding mechanisms underlying unlock maximum nanotechnology, facilitating smooth transition research findings from laboratory practice.

Language: Английский

Citations

8
Current trends in epigenetic, cellular and molecular pathways in management of rheumatoid arthritis DOI
Rashita Makkar, Aayush Sehgal, Sukhbir Singh

et al.

Inflammopharmacology, Journal Year: 2023, Volume and Issue: 31(4), P. 1577 - 1588

Published: June 19, 2023

Language: Английский

Citations

14
Exploring the Therapeutic Potential of Ammodaucus leucotrichus Seed Extracts: A Multi-Faceted Analysis of Phytochemical Composition, Anti-Inflammatory Efficacy, Predictive Anti-Arthritic Properties, and Molecular Docking Insights DOI Creative Commons
Cheima Djehiche,

Nadia Benzidane,

Hanène Djeghim

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(3), P. 385 - 385

Published: March 18, 2024

Ammodaucus leucotrichus exhibits promising pharmacological activity, hinting at anti-inflammatory and anti-arthritic effects. This study investigated seed extracts from using methanol n-hexane, focusing on properties. The extract outperformed the n-hexane diclofenac, a reference drug, in trypsin inhibition (85% vs. 30% 64.67% 125 μg/mL). For inhibition, IC50 values were 82.97 μg/mL (methanol), 202.70 (n-hexane), 97.04 (diclofenac). Additionally, surpassed diclofenac BSA (bovine serum albumin) denaturation (90.4% 22.0% 51.4% 62.5 14.30 5408 42.30 Gas chromatography-mass spectrometry (GC-MS) revealed 59 58 secondary metabolites extracts, respectively. higher therapeutic activity of was attributed to hydroxyacetic acid hydrazide, absent extract. In silico docking studies identified 28 compounds with negative binding energies, indicating potential inhibition. 2-hydroxyacetohydrazide displayed superior inhibitory effects compared diclofenac. Further mechanistic are crucial validate as drug candidate for rheumatoid arthritis treatment.

Language: Английский

Citations

5
PTEN: an emerging target in rheumatoid arthritis? DOI Creative Commons
Zhou Pan,

Xingwen Meng,

Zhimin Nie

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: April 26, 2024

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a critical tumor suppressor protein that regulates various biological processes such as cell proliferation, apoptosis, inflammatory responses by controlling the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PI3K/AKT) signaling pathway. PTEN plays crucial role in pathogenesis of rheumatoid arthritis (RA). Loss may contribute to survival, pro-inflammatory cytokine release fibroblast-like synoviocytes (FLS). Also, persistent PI3K increases myeloid cells' osteoclastic potential, enhancing localized bone destruction. Recent studies have shown expression synovial lining RA patients with aggressive FLS minimal. Experimental upregulation could reduce damage caused RA. Nonetheless, complete comprehension aberrant drives progression its interactions other molecules remains elusive. This review dedicated promoting thorough understanding mechanisms aims furnish pertinent theoretical support for forthcoming endeavors both basic clinical research within this domain.

Language: Английский

Citations

5
Nanoformulation-assisted microneedle transdermal drug delivery system: An innovative platform enhancing rheumatoid arthritis treatment DOI Open Access

Yao Wendong,

Yan Xingxing,

Xie Xianze

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 178, P. 117219 - 117219

Published: July 30, 2024

A transdermal delivery system offers high bioavailability and favorable patient adherence, constituting an optimal approach for localized administration in rheumatoid arthritis (RA) treatment. However, the stratum corneum (SC) impedes efficiency of conventional drug systems. Microneedles (MNs) can temporarily create micropores within SC, enabling distribution via bypassing this barrier enhancing effectiveness. Notably, MNs provide a painless method through skin may directly modulate inflammation immune cells by delivering drugs lymphatic during administration. MN is not suitable with low water solubility stability. Additionally, major concerns exist regarding safety using highly cytotoxic drugs, given that it could result local concentration at site. While exhibit some degree targeted to inflammatory environment, their targeting remains suboptimal. Nanoformulations have potential significantly address limitations RA treatment improving targeting, solubility, stability, biocompatibility. Therefore, review provides concise overview advantages, disadvantages, mechanisms different types It specifically focuses on application advantages combining nanoformulation summarizes current trends development nanoformulations combined field treatment, offering theoretical support future advancements clinical applications.

Language: Английский

Citations

5
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study DOI Creative Commons
Marino Paroli, Andrea Becciolini, Elena Bravi

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(8), P. 1480 - 1480

Published: Aug. 17, 2023

Background: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for treatment of rheumatoid arthritis (RA). However, data on retention rate TOFA therapy are still far from definitive. Objective: The goal this study is add new real-world in a cohort RA patients followed long period time. Methods: A multicenter retrospective subjects treated with as monotherapy or combination conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) conducted 23 Italian tertiary rheumatology centers. considered up 48 months all included patients. assessed Kaplan-Meier method. Hazard ratios (HRs) discontinuation were obtained using Cox regression analysis. Results: We enrolled total 213 Data analysis revealed that 86.5% (95% CI: 81.8-91.5%) at month 12, 78.8% 78.8-85.2%) 24, 63.8% 55.1-73.8%) 36, and 59.9% after starting treatment. None factors analyzed, including number previous treatments received, disease activity duration, presence factor and/or anti-citrullinated protein antibody, comorbidities, predictive rate. Safety comparable those reported registration studies. Conclusions: demonstrated setting. This result, together safety obtained, underscores viable alternative who have failed csDMARD biologic DMARDs (bDMARDs). Further large, long-term observational studies urgently needed confirm these results.

Language: Английский

Citations

11
Natural biomimetic nano-system for drug delivery in the treatment of rheumatoid arthritis: a literature review of the last 5 years DOI Creative Commons
Jingyuan Li, Wei Li,

Liping Zhuang

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: May 9, 2024

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized primarily by synovitis, leading to the destruction of articular cartilage and bone ultimately resulting in joint deformity, loss function, significant impact on patients’ quality life. Currently, combination anti-rheumatic drugs, hormonal biologics used mitigate progression. However, conventional drug therapy has limited bioavailability, long-term use often leads resistance toxic side effects. Therefore, exploring new therapeutic approaches for RA great clinical importance. Nanodrug delivery systems offer promising solutions overcome limitations drugs. Among them, liposomes, first nanodrug system be approved application still widely studied, demonstrate ability enhance efficacy with fewer adverse effects through passive or active targeting mechanisms. In this review, we provide review research progress mechanisms various natural biomimetic nano-delivery therapy. Additionally, predict development trends prospects these systems, offering directions precision treatment RA.

Language: Английский

Citations

4